Lung function and radiological findings 1 year after COVID-19: a prospective follow-up

Julia Tarraso1, Belen Safont1, Juan A. Carbonell-Asins2, Estrella Fernandez-Fabrellas3, Jose N. Sancho-Chust4, Elsa Naval5, Beatriz Amat6, Susana Herrera7, Jose A. Ros8, Juan J. Soler-Cataluna9, Jose A. Rodriguez-Portal10, Ada L. Andreu11, Margarita Marin12, Juan L. Rodriguez-Hermosa13, Cruz Gonzalez-Villaescusa1, Joan B. Soriano14, Jaime Signes-Costa1* and COVID-FIBROTIC study team

Abstract

Background: The coronavirus disease (COVID-19) pandemic has already affected more than 400 million people, with increasing numbers of survivors. These data indicate that a myriad of people may be affected by pulmonary sequelae of the infection. The aim of this study was to evaluate pulmonary sequelae in patients with bilateral COVID-19 pneumonia according to severity 1 year after hospital discharge.

Methods: COVID-FIBROTIC is a multicenter prospective observational cohort study for admitted patients with bilateral COVID-19 pneumonia. Pulmonary functional outcomes and chest computed tomography sequelae were analyzed 12 months after hospital discharge and we classified patients into three groups according to severity. A post hoc analysis model was designed to establish how functional test changed between groups and over time. A multivariable logistic regression model was created to study prognostic factors for lung diffusion impairment and radiological fibrotic-like changes at 12 months.

Results: Among 488 hospitalized patients with COVID-19 pneumonia, 284 patients had completed the entire evaluation at 12 months. Median age was 60.5 ± 11.9 and 55.3% were men. We found between-group differences in male sex, length of hospital stay, radiological involvement and inflammatory laboratory parameters. The functional evaluation of pulmonary sequelae showed that severe patients had statistically worse levels of lung diffusion at 2 months but no between group differences were found in subsequent controls. At 12-month follow up, however, we found impaired lung diffusion in 39.8% unrelated to severity. Radiological fibrotic-like changes at 12 months were reported in 22.7% of patients (102/448), only associated with radiological involvement at admission (OR: 1.55, 95% CI 1.06–2.38; p = 0.02) and LDH (OR: 0.99, 95% CI 0.98–0.99; p = 0.046).

Conclusion: Our data suggest that a significant percentage of individuals would develop pulmonary sequelae after COVID 19 pneumonia, regardless of severity of the acute process.

Keywords: Pulmonary sequelae, COVID 19, Lung fibrosis

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
may progress to acute respiratory distress syndrome (ARDS) [2]. A percentage of ARDS survivors will develop fibrotic pulmonary lesions related to fibroblast accumulation and collagen deposition and other extracellular matrix components [3]. Despite use of protective ventilation protocols, these restrictive changes will reduce quality of life [3, 4] and in some cases result in permanent disabilities. Moreover, a percentage of patients surviving other pneumonias caused by coronavirus such as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), developed long-term functional impairment and fibrotic radiological changes. Older age and male sex were identified as risk factors for unfavorable outcomes and development of pulmonary fibrosis, and correlated with severity and duration of acute illness [5–9].

In the acute phase of COVID-19, mechanical ventilation patient autopsies showed more pronounced hyperplastic and metaplastic changes of pneumocytes and interstitial fibrosis than those receiving conventional oxygen [10]. Early high resolution computed tomography (HRCT) appearance of fibrotic changes have been reported during hospitalization, suggesting that the direct effect of the virus on pulmonary alveolar and endothelial cells combined with an aberrant local immune response could induce pulmonary fibrosis in predisposed patients [11]. Comparing patient HRCT at 60 and 100 days after discharge, there is improvement in the consolidation and extent of ground-glass opacities in images but only a gradual improvement in reticular lesions [12].

Approximately a third of patients with severe pneumonia presented with fibrotic changes, defined as presence of parenchymal bands, traction bronchiectasis and/or honeycombing within 6 months of discharge. In these patients, need for non-IMV was identified as a risk factor [13], and 25% of patients admitted for COVID-19 pneumonia maintained radiological alterations 1 year after discharge, with the most frequent residual alteration (13%) being subpleural reticular/cystic lesions [14].

A recently published study analyzed functional changes over 1 year in severe COVID-19 pneumonia survivors, excluding mechanically ventilated patients. They report pulmonary function improvement at follow-up, but 33% of patients showed diffusing capacity of the lungs for carbon monoxide (DLCO) abnormalities, while fibrotic changes on HRCT were described in less than 5% [15].

We hypothesized that patients with COVID-19 pneumonia may develop pulmonary sequelae regardless of treatment or not with mechanical ventilation. The aim of our study was to investigate persistent fibrotic-like lesions and changes in lung function in a cohort of patients with bilateral COVID-19 pneumonia 1 year after hospital discharge.

Methods

Study design and participants
COVID-FIBROTIC (clinicaltrials.gov NCT04409275) is a prospective, multicenter, observational follow-up study of patients admitted for bilateral COVID-19 pneumonia in 12 hospitals in Spain. Diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was based on centers of disease control (CDC) criteria, with all patients confirmed by reverse transcription polymerase chain reaction (PCR). Diagnosis of COVID-19 pneumonia was established in accordance with World Health Organization (WHO) interim guidance if patients met any of the following criteria: oxygen saturation (SpO2) < 94% in room air at sea level, arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) ratio < 300 mmHg, respiratory frequency > 30 breaths/min, or lung infiltrates > 50% [16]. The extent of pneumonia at the time of emergency room diagnosis was quantified by adapting the Radiographic Assessment of Lung Edema (RALE) score to COVID-19 (minimum 0–maximum 8) [17]. When there was no prior history of pulmonary diseases (except for asthma or sleep apnea) or uncontrolled cardiac or renal failure, findings were attributed to SARS-CoV-2 infection.

All patients discharged from respiratory services aged over 18 with a life expectancy > 1 year were invited to participate. Patients with unilateral COVID-19 pneumonia, a previous diagnosis of interstitial lung disease (ILD) or chronic obstructive pulmonary disease (COPD) and/or with difficulties in attending the centers for follow-up visits were excluded. Patients who experienced a pulmonary embolism during admission were not excluded if they were properly anticoagulated and had shown embolism resolution in a previous angioCT.

Pulmonary function testing (PFT) and 6-m walk test (6MWT)

Pulmonary function tests (PFT) were performed in the respiratory functional testing laboratory in all participating centers and included determination of lung volumes [total lung capacity (TLC), residual volume (RV), functional residual capacity (FRC) using plethysmography], and spirometry [forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1) and FEV1/FVC ratio]. DLCO was determined by the single breath technique using an infrared analyzer, correcting for hemoglobin values. All procedures were performed according to American Thoracic Society (ATS) and European Respiratory Society (ERS) guidelines [18–21].

The 6-min walk test (6MWT) measures the distance that a patient can walk quickly on a flat, hard surface in a period of 6 min. It evaluates the global and integrated responses of all systems involved during exercise,
including pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood, neuromuscular units and muscle metabolism [22, 23].

**Imaging tests**

Control chest X-rays (CXRs) were performed in all patients 2 months after discharge using standardized techniques with computed radiography equipment. Pulmonary damage was quantified using the RALE score. HRCT scans (SOMATOM, Siemens, Germany; AQUILION, Toshiba, Japan; OPTIMA, General Electric, USA) were obtained with subjects in the supine position during breath hold at end-inspiration. Axial reconstructions were performed with a slice thickness of 1 mm, with 1 mm increment, 512 mm × 512 mm (resolution 0.625 mm/10). The same protocol was used in each center, adjusted to the different CT machines. HRCT images were evaluated for presence of ground-glass opacities (GGO), consolidations, bronchiectasis, parenchymal bands and reticulations as defined by the Fleischner society glossary of terms [24]. Fibrotic-like changes on HRCT were defined as presence of traction bronchiectasis, parenchymal bands and/or reticular pattern [25, 26]. Experienced chest radiologists in each centers, blinded to all clinical and functional data, evaluated the images. CT scans performed at 1 year were also compared with the 2-month scan.

**Procedures**

During the screening visit (30 days after hospital discharge), demographic data (age, sex, ethnicity) and medical history (smoking, hypertension, diabetes, previous respiratory, cardiac or renal history and concomitant medication) were collected. Data associated with the acute episode were also collected (days of symptom onset, intensity of dyspnea, extent of pneumonia on diagnostic X-ray in the emergency room, maximum radiological extent during admission, days of admission, maximum respiratory support and inflammatory laboratory values). All data were retrieved from electronic medical records and de-identified data were entered into an electronic database (Veridata™ EDC). Patients were assessed 2 months after discharge (visit 1, V1) by collecting residual dyspnea using the modified British Medical Research Council (mMRC) [27], CXR and PFT. Patients with impairment in PFT (FVC <80% without FEV1/FVC <70 and/or DLCO <80%) and/or persistent radiological alteration on CXR underwent thoracic HRCT [28]. Functional changes, exercise capacity using the 6MWT and evolution of dyspnea were assessed at 2 (V1), 6 (visit 2, V2) and 12 months (visit 3, V3) after discharge, repeating chest HRCT in patients without complete resolution at 2-month CT scan. No further treatment was indicated.

For further analysis, patients were stratified according to WHO Ordinal Outcomes Scale [29] into three groups, depending on the maximum respiratory support needed:

1. **Group 1**: hospitalized mild disease (scale 4): hospitalized patients who required supplemental oxygen by mask or nasal prongs.
2. **Group 2**: hospitalized severe disease (scale 5): hospitalized patients who required non-invasive ventilation (non-IMV) or high flow nasal oxygen cannula (HFNC).
3. **Group 3**: hospitalized critical disease (scale 6–7): hospitalized patients who required respiratory support by intubation and invasive mechanical ventilation (IMV).

**Statistical analysis**

We followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) [30] guidelines for reporting observational studies. We calculated the required sample size using the ‘nsize’ command in Stata 12.1 based on data published by Hui [31], who describe a proportion of fibrotic radiological abnormalities on chest X-ray on 27.8% patients (SARS survivors in 2003) assuming a maximum error of 5% and 95% confidence.

Qualitative variables were described using frequencies and percentages, and quantitative variables by means and standard deviation. Normality for continuous variables was checked using the Shapiro-Wilks test and if their normal distribution was not confirmed, variables were expressed with median and interquartile range.

Mean comparison was carried out using the Student t-test in the presence of normality, and if otherwise, using the Mann–Whitney U test. For qualitative variables, comparison of percentages between groups was carried out using Fisher’s exact test for dichotomous variables or chi-square test for contingency tables with more than two categories. Patient pulmonary function at follow-up was assessed with mixed linear models for quantitative outcomes, with individual identification key as random effect and time and/or severity status and interaction as independent factors. Cochran-Q test was used in the case of dichotomous outcomes. Factors associated with diffusion impairment and fibrotic pattern at 12 months were studied using multivariable logistic regression. The variables for the multivariable analysis were selected using Akaike’s Information Criterion in a backward-forward stepwise procedure.
Effect of time and severity in DLCO, 6MM and FVC was evaluated using linear mixed models with time (V1, V2, V3) and severity (mild, moderate, severe) as fixed effects and individuals as random effect; interaction between severity and time was also included. Compound symmetry was used for correlation between time measures of same individual. Similarly dyspnea was dichotomized into 2 or more versus less than 2, model proposed was a generalized linear mixed model with time, severity and interaction between both fixed effects and individuals as random effect. Post-hoc analysis was carried out in the interaction term with p value adjustment according to Bonferroni method for 36 tests.

Results
Between May 1 and July 31, 2020, 932 patients were attended for COVID-19 pneumonia in participating hospitals, 481 of whom were initially considered for follow-up. At the end of the study, we retrieved full data in 377, 312 and 284 patients at 2, 6 and 12 months, respectively (Fig. 1). Most of the data were lost due to pandemic restrictions.

Analysis of the cohort that completed the 12-month period showed a mean age of 60.5 (11.9) years, and 55.3% (157/284) of them were men, which significantly increased as did severity: 50.2% (105/209) vs. 60.9% (14/23) vs. 73.1% (38/52) [p = 0.010]. We also found between-group differences in length of hospital stay [p < 0.001], RALE scores [p < 0.001] and laboratory parameters (lower lymphocyte count and higher peak levels of lactated dehydrogenase, C-reactive protein, ferritin and D-dimer) [all p < 0.001]. In contrast, there were no significant differences between groups in age, comorbidities, smoking, or body mass index (BMI) (Table 1).

The average time to post-hospital discharge appointments was 63 (14) days for V1, 181 (10) for V2 and 365 (17) for V3.

Pulmonary function tests
Analyzing pulmonary function tests from the whole cohort, 53.8% (203/377) of patients had diffusion impairment (<80% of predicted DLCO) at 60 days, with an improving trend at 180 and 365 days (46.8% [146/312] and 39.8% [113/284], respectively) [p < 0.001]. The mean (% of predicted) DLCO in V1, V2 and V3 was 78.5 (19.1), 81.6 (16.4) and 84 (16.4), respectively [p < 0.001] (Table 2). However, turning to changes in diffusion (% of predicted DLCO) as a function of severity (groups 1, 2 and 3) and dynamics over time, we only found significant differences between mild and moderate [p = 0.001] or severe [p < 0.001] patients at 2 months (V1) (Fig. 2A).

Restrictive abnormality (FVC < 80% of predicted) across the whole cohort was present in 14.3% [54/377], 9.3% [29/312] and 6.7% [19/284] of patients at 2, 6 and 12 months, respectively [p = 0.001] and mean FVC (% of predicted) was 99 (17.9), 100.8 (16.5) and 104.2 (16) at 2, 6 and 12 months [p < 0.001] (Table 2). Nevertheless, we did not find significant differences when we analyzed FVC (% of predicted) as a function of severity and time (Fig. 2B).

We next analyzed dyspnea across the entire cohort. Dyspnea ≥ 2 at mMRC scale was 21.5% [59/275], 11.3% [31/275] and 9.8% [27/275] at 2, 6 and 12 months (Table 2) and association between dyspnea and follow-ups was found to be significant [p < 0.001]. However, when evaluating the possible changes between severity groups during follow-up, no significant differences were found (Fig. 2C).

We did not found differences between-groups on static volumes and, although we found differences at 6MWT, a decrease in the distance walked was obtained (mean 523.6 vs. 520.6 vs. 518.8; [p = 0.004]) (Table 2). However, severity might be a confounding factor because no significant trend was found when adjusting by it (Additional file 1: Fig. S1).

Associated factors with altered DLCO < 80% at 12 months according to multivariable regression were age (OR 1.04, 95% CI 1.00–1.07, p = 0.013), female sex (OR: 6.22, 95% CI 2.77–15.04, p = 0.001), BMI (OR: 0.91, 95% CI 0.84–0.99, p = 0.001) and ferritin levels (OR: 1.00, 95% CI 1.00–1.01, p = 0.008) (Table 3).

Radiological findings
According to the study protocol, chest CT was indicated 2 months after discharge in patients with persistent dyspnea, pulmonary function test alteration or abnormal chest radiography. At V1, we performed HRCT on 325 patients, 38.4% of whom showed complete resolution (125/325). In the remaining 200 patients, the most frequent radiological pattern was GGO, reported in 73.5% [147/200] (32% when we consider the study cohort [147/448]), with between-group differences (Additional file 2: Table S1). According to protocol, patients underwent a new chest CT 1 year after discharge if abnormal changes had been present in the previous one. Finally, 156 patients out of 200 (78%) had CT at 12 months (Fig. 1) and any radiological alteration persisted in 78.8% of patients with a second CT [123/156], 27.4% when considering our study cohort [123/448]. Regarding these CT abnormalities, GGO was found in 45.5% of the performed CT [71/156] (or 15.8% on the study cohort [71/448]), reticular pattern in 34% [53/156] (11.8% [53/448]); traction bronchiectasis in 30.8% [48/156] (10.7% [48/448]) and parenchymal bands in 33.4% [52/156] (11.6% [52/448]). In total, fibrotic-like sequelae
COVID-19 pneumonia patients enrolled between May 1-31 July 2020 in participating hospitals (N = 932)

451 excluded
- 47 pre-existing respiratory disease
- 76 did not provide consent
- 210 logistic reasons (out of area)
- 118 due to investigator’s decision

Initially considered for the study
N = 481

33 excluded
23 withdrew consent
10 Recent COPD diagnosis

Study population
N = 448

Endpoint 1
Description of PFT at 2, 6 and 12 months

3 deaths
25 loss to follow-up
43 hospital’ incapacity

PFT available at 2 months
n = 377

PFT available at 6 months
n = 312

PFT available at 12 months
n = 284

Endpoint 2
Description chest CT changes at 2 and 12 months

81 resolved
42 hospital’ incapacity

CT performed at 2 months
n = 325

125 resolved

13 50 loss to follow-up
10 near appointment
8 hospital’ incapacity

CT performed 12 months
n = 156

50 loss to follow-up
40 hospital’ incapacity

Fig. 1 Flow chart of patients discharged from participating hospitals included in the COVID-FIBROTIC cohort. At 2 months a CT scan was ordered when there were alterations at chest radiography and/or pulmonary function test abnormalities. COPD chronic obstructive pulmonary disease, PFT pulmonary functional test, CT computed tomography.
Table 1  Characteristics of completed patients

|                      | Severity group 1 | Severity group 2 | Severity group 3 | Total      | p-value |
|----------------------|------------------|------------------|------------------|------------|---------|
|                      | n = 209          | n = 23           | n = 52           | n = 284    |         |
| Age, years           | 59.9 (12.5)      | 61.4 (10.7)      | 62.7 (9.6)       | 60.5 (11.9) | 0.28    |
| Male sex             | 105 (50.2%)      | 14 (60.9%)       | 38 (73.1%)       | 157 (55.3%) | 0.01    |
| BMI, kg/m²           | 28.0 (4.8)       | 27.3 (4.1)       | 28.0 (4.4)       | 28.0 (4.7)  | 0.75    |
| Never-smoker         | 122 (58.4%)      | 17 (73.9%)       | 25 (48.1%)       | 164 (57.7%) | 0.14    |
| Comorbidities        |                  |                  |                  |            |         |
| Pulmonary diseasea   | 39 (18.7%)       | 4 (17.4%)        | 7 (13.5%)        | 50 (17.6%)  | 0.69    |
| Hypertension         | 82 (39.2%)       | 5 (21.7%)        | 25 (48.1%)       | 112 (39.4%) | 0.09    |
| Diabetes             | 30 (14.4%)       | 1 (4.3%)         | 10 (19.2%)       | 41 (14.4%)  | 0.26    |
| Cardiovascular disease| 21 (10.0%)     | 3 (13%)          | 4 (7.7%)         | 28 (9.9%)   | 0.74    |
| Admission RALE score | 3.2 (1.6)        | 4.1 (1.5)        | 4.3 (1.7)        | 3.5 (1.7)   | < 0.001 |
| Peak RALE score      | 3.2 (1.6)        | 4.2 (1.8)        | 6.0 (1.6)        | 6.5 (1.6)   | < 0.001 |
| Length of hospital stay, days | 9.2 (5.1) | 19.9 (6.4) | 43.6 (27.5) | 16.5 (18.4) | < 0.001 |
| Laboratory findingsb |                  |                  |                  |            |         |
| Lymphocytes, × 10⁹/L | 1.0 (0.5)        | 0.7 (0.5)        | 0.5 (0.3)        | 0.9 (0.5)   | < 0.001 |
| LDH, U/L             | 514.0 (224.8)    | 592.5 (221.7)    | 873.8 (360.1)    | 590.7 (291.8) | < 0.001 |
| C-reactive protein, mg/L | 81.7 (79.9)   | 222.3 (120.2)    | 234.5 (145.4)    | 121.3 (118.4) | < 0.001 |
| Ferritin, ng/mL      | 838.2 (713.6)    | 1506.1 (1031.9)  | 2133.3 (1469.0)  | 1151.3 (1064.2) | < 0.001 |
| Fibrinogen, g/L      | 64 (1.6)         | 8.2 (2.2)        | 21.8 (8.26)      | 9.5 (36.2)  | 0.08    |
| D-dimer, ng/mL       | 1957.6 (4280.8)  | 3106.3 (4984.6)  | 10,994.5 (10,535.6) | 3631.2 (6796.3) | < 0.001 |

Data are n (%) or mean (SD). Severity group 1: mild. Severity group 2: moderate. Severity group 3: severe
BMI body mass index, RALE radiographic assessment of lung edema, LDH lactate dehydrogenase
a Pulmonary disease: asthma, obstructive sleep apnea
b All laboratory findings are peak values except for lymphocytes which is the lowest value

Table 2  Pulmonary function test of patients at follow-up

|                      | First follow-up (2 months) | Second follow-up (6 months) | Third follow-up (12 months) | p-value |
|----------------------|----------------------------|----------------------------|-----------------------------|---------|
|                      | n = 377                    | n = 312                    | n = 284                     |         |
| FVC, L               | 3.50 (1.08)                | 3.55 (1.02)                | 3.66 (1.05)                 | < 0.001 |
| FVC, % pred          | 98.99 (17.86)              | 100.76 (16.49)             | 104.16 (16.10)              | < 0.001 |
| FVC < 80%, pred      | 54 (14.32%)                | 29 (9.29%)                 | 19 (6.69%)                  | < 0.001 |
| FEV1, L              | 2.79 (0.86)                | 2.81 (0.82)                | 2.89 (0.84)                 | < 0.001 |
| FEV1, % pred         | 98.58 (16.93)              | 100.12 (16.07)             | 103.53 (15.63)              | < 0.001 |
| FEV1/FVC             | 79.58 (6.87)               | 79.03 (6.30)               | 78.75 (5.92)                | 0.004   |
| D_co, % pred         | 78.47 (19.14)              | 81.61 (16.37)              | 84.03 (16.37)               | < 0.001 |
| D_co < 80%, pred     | 203 (53.80%)               | 146 (46.79%)               | 113 (39.78%)                | < 0.001 |
| D_co/V_a, % pred     | 92.55 (17.37)              | 95.20 (17.25)              | 95.66 (17.16)               | 0.001   |
| D_co/V_a < 80%, pred | 83 (22.02%)                | 57 (18.26%)                | 48 (16.90%)                 | 0.02    |
| TLC, % pred          | 95.61 (14.90)              | 96.47 (14.33)              | 96.88 (14.51)               | 0.08    |
| RV, % pred           | 96.90 (23.65)              | 96.75 (23.18)              | 95.02 (23.80)               | 0.72    |
| 6MWT distance, m     | 523.63 (94.30)             | 520.57 (104.53)            | 518.82 (101.66)             | 0.004   |
| mMRCa                | 0–1                        | 216 (78.54%)               | 244 (88.72%)                | < 0.001 |
|                      | ≥ 2                        | 59 (21.45%)                | 31 (11.27%)                 |         |

Data are n (%) or mean (SD)
FVC forced vital capacity, FEV1 forced expiratory volume in one second, D_co diffusing capacity for carbon monoxide, V_a alveolar volume, TLC total lung capacity, RV residual volume, 6MWT 6 min walk test (m), mMRC modified British Medical Research Council (dyspnea)
a Dyspnea was registered on 275 patients
were found at 12 months in 65.4% of the performed CT [102/156], 22.7% when considering our study cohort [102/448] (Table 4). In addition, these changes were more frequent among more severe patients, with significant between-group differences [p<0.001].

The only factors associated with fibrotic pattern at 1 year according to multivariable regression were radiological involvement at admission (OR: 1.55, 95% CI 1.06–2.38; p = 0.02) and LDH (OR: 0.99, 95% CI 0.98–0.99; p = 0.046) (Table 5).

**Discussion**

In this multicenter prospective study of hospitalized patients with bilateral COVID-19 pneumonia of variable severity, we analyzed functional and radiological sequelae 12 months after hospital discharge, and we have found that reduced lung diffusion persisted in almost 40% of patients (DLCO<80%) 1 year after acute COVID-19 infection. Furthermore, we identified radiological fibrotic-like changes on chest CT in almost 23% of our study cohort [n=448]. However, these sequelae were not associated with other markers of severity previously described in ARDS cases [32], such as need for mechanical ventilation.

Along with an increasing number of people affected over time, survival has improved since the start of the pandemic [33], but with the consequence that millions of survivors could be affected by pulmonary sequelae of COVID-19, which could lead to a clear deterioration in quality of life.

Although functional recovery from severe COVID-19 pneumonia occurs within 1 year after discharge, approximately one third of patients (39.8%) still have decreased DLCO. These findings are in line with the results from a Chinese cohort [15], albeit excluding patients requiring invasive mechanical ventilation, and are consistent with a recently published meta-analysis [34]. Among our key findings is that although more severe patients showed higher diffusion impairment 2 months after discharge,
this difference lost significance at 6 and 12 months. Furthermore, analyzing factors related to the persistence of DLCO deterioration, 1 year after discharge, we found association with age, female sex, body mass index and ferritin, but need of invasive mechanical ventilation (IMV) (most severe disease) was surprisingly not. The association between female sex and DLCO disturbances is consistent with previously published results at 6 [35, 36] and 12 months in COVID-19 pneumonia survivors [15], with no clear explanation forthcoming.

A recent systematic review showed that histopathological findings of diffuse alveolar damage caused by COVID-19 are indistinguishable from those provoked by other causes. At final, chronic/fibrotic phase was identified, showing a honeycomb lung with collagen fibrosis of the alveolar spaces and an interstitium with thickening of the alveolar wall together with squamous metaplasia.

### Table 3  Multivariate logistic regression to predict the diffusion impairment at 12 months

|                      | Total N | Missing | Univariable analysis | Multivariable analysis |
|----------------------|---------|---------|----------------------|------------------------|
|                      | OR (95% CI) | p-value | OR (95% CI) | p-value |
| Age, years           | 283     | 1       | 1.02 (1.00–1.04) | 0.01 | 1.04 (1.00–1.07) | 0.013 |
| Female sex           | 284     | 0       | 2.53 (1.56–4.14) | 0.001 | 6.22 (2.77–15.04) | 0.001 |
| BMI, kg/m²            | 278     | 6       | 0.98 (0.93–1.03) | 0.48 | 0.91 (0.84–0.99) | 0.036 |
| Smoker               | 283     | 1       | 1.48 (0.91–2.43) | 0.11 | N/A                | N/A |
| Pulmonary disease     | 284     | 0       | 0.66 (0.34–1.25) | 0.21 | N/A                | N/A |
| Hypertension          | 284     | 0       | 1.02 (0.63–1.66) | 0.91 | N/A                | N/A |
| Diabetes              | 284     | 0       | 1.08 (0.54–2.11) | 0.81 | N/A                | N/A |
| Cardiovascular disease| 284     | 0       | 2.18 (0.99–4.91) | 0.05 | NA                 | NA |
| Admission RALE score  | 278     | 6       | 1.08 (0.94–1.25) | 0.24 | N/A                | N/A |
| Peak RALE score       | 278     | 6       | 1.07 (0.94–1.21) | 0.25 | N/A                | N/A |
| Length of hospital stay, days | 280   | 4       | 1.01 (1.00–1.03) | 0.01 | NA                 | NA |
| Lymphocytes*; x 10⁹/L | 240     | 44      | 0.84 (0.49–1.40) | 0.51 | N/A                | N/A |
| LDH, U/L              | 241     | 43      | 1.00 (1.00–1.01) | 0.02 | NA                 | NA |
| C-reactive protein, mg/L | 249 | 35      | 1.00 (0.99–1.00) | 0.14 | N/A                | N/A |
| Ferritin, ng/mL       | 204     | 80      | 1.00 (0.99–1.00) | 0.15 | 1.00 (1.00–1.01) | 0.008 |
| Fibrinogen, g/L       | 178     | 106     | 1.07 (1.00–1.27) | 0.39 | 1.02 (0.99–1.26) | 0.79 |
| D-dimer, ng/mL        | 252     | 32      | 1.00 (1.00–1.01) | 0.01 | 1.00 (1.00–1.01) | 0.07 |
| Severity group 3      | 284     | 0       | 2.25 (1.22–4.20) | 0.009 | 1.05 (0.33–3.33) | NA |

**OR** odds ratio, CI confidence interval, BMI body mass index, RALE radiographic assessment of lung edema, LDH lactated dehydrogenase

* All laboratory findings are peak values except for lymphocytes which is the lowest value

Variables selected according to backward-forward stepwise selection AIC

### Table 4  Chest CT at 12-month follow-up according to severity groups

|                      | Severity group 1 | Severity group 2 | Severity group 3 | Total |
|----------------------|------------------|------------------|------------------|-------|
|                      | n = 81           | n = 18           | n = 57           | n = 156 |
| Normal CT pattern    | 28 (34.6%)       | 2 (11.1%)        | 3 (5.3%)         | 33 (21.2%) | 0.001 |
| Consolidation        | 14 (17.3%)       | 0 (0%)           | 11 (19.3%)       | 25 (16%) | 0.12 |
| GGO                  | 29 (35.8%)       | 11 (61.1%)       | 31 (54.4%)       | 71 (45.5%) | 0.02 |
| Reticular pattern    | 26 (32.1%)       | 4 (22.2%)        | 23 (40.4%)       | 53 (33.9%) | 0.36 |
| Traction bronchiectasis | 14 (17.3%)     | 6 (33.3%)        | 28 (49.1%)       | 48 (30.8%) | 0.001 |
| Parenchymal bands    | 14 (17.3%)       | 6 (33.3%)        | 32 (56.1%)       | 52 (33.4%) | 0.001 |
| Fibrosis-like changes* | 39 (48.1%)   | 15 (83.3%)       | 48 (84.2%)       | 102 (65.4%) | 0.001 |

Data are n (%). Severity group 1: mild. Severity group 2: moderate. Severity group 3: severe

CT computed tomography, GGO ground glass opacity

* Fibrotic-like changes: defined as the presence of traction bronchiectasis, reticular pattern and/or parenchymal bands
of the alveoli [37]. These changes have been reported in 43% of 30 COVID-19 autopsies, and were associated with longer duration of illness and hospitalization and need for mechanical ventilation [38].

The ARDS repair process involves rapid fibroblast proliferation and this leads to extracellular matrix deposition [3], which in a number of patients will remain, resulting in residual fibrosis. However, our group found an increase in serum biomarkers of pulmonary fibrosis (MMP7, MMP1, and periostin) in patients with early fibrotic changes in chest CT at 2 months after hospital discharge [36], not only in IMV patients but also in those treated with conventional or high flow nasal cannula oxygen. A number of environmental and patient-specific factors may also contribute to this fibroproliferation.

In our study cohort, any radiological abnormality at 12 months persisted in 27% [123/448] of patients. This percentage is similar to that obtained by Pan et al. [53/209] [14] and somewhat higher than that recently published by Wu et al. [24], although patients with invasive mechanical ventilation were excluded in their cohort [15].

We define fibrotic-like changes as the presence of traction bronchiectasis, parenchymal bands and/or reticular pattern [25, 26, 39]. The analysis of fibrotic-like changes in our study population yielded results (23% [102/448]) similar to those found by a recent systematic review reporting radiological fibrotic-like sequelae in 21% of patients 1 year after discharge [40], although other meta-analyses have detected a higher percentage (29%) [34]. In our study, fibrotic-like changes were only associated with radiological involvement at admission and peak LDH levels. Although more severe patients (requiring IMV) had a significantly higher percentage of fibrotic sequelae than the mild group (84.2% [48/57] vs. 48.1% [39/81]), no significance was found between severity and fibrotic-like changes in the multivariable model [p = 0.15].

Mechanical ventilation is a recognized factor in fibrosis development [32], caused by mechanical stress and an induced “biotraumatic” inflammatory response involving cytokine, chemokine and growth factor release. This also supports our finding that radiological involvement at admission and peak LDH levels. Although more severe patients (requiring IMV) had a significantly higher percentage of fibrotic sequelae than the mild group (84.2% [48/57] vs. 48.1% [39/81]), no significance was found between severity and fibrotic-like changes in the multivariable model [p = 0.15].

| Table 5 | Multivariable logistic regression to predict the fibrotic-like impairment at 12 months |
|---------|---------------------------------|------------------|------------------|
|         | Total N | Missing | Univariable analysis | Multivariable analysis |
|         |         |         | OR (95% CI) | p-value | OR (95% CI) | p-value |
| Age, years | 156 | 0 | 1.01 (0.98–1.05) | 0.37 | 0.99 (0.93–1.05) | 0.77 |
| Female sex | 156 | 0 | 0.50 (0.25–1.00) | 0.05 | N/A | N/A |
| BMI, kg/m² | 144 | 12 | 0.93 (0.85–1.00) | 0.08 | N/A | N/A |
| Smoker | 155 | 1 | 1.32 (0.68–2.61) | 0.40 | N/A | N/A |
| Pulmonary disease | 156 | 0 | 0.93 (0.38–2.35) | 0.87 | 2.08 (0.49–9.68) | 0.32 |
| Hypertension | 156 | 0 | 0.94 (0.48–1.85) | 0.87 | 1.13 (0.34–3.69) | 0.83 |
| Diabetes | 156 | 0 | 0.95 (0.42–2.23) | 0.90 | N/A | N/A |
| Cardiovascular disease | 156 | 0 | 2.18 (0.99–4.91) | 0.05 | NA | NA |
| Admission RALE score | 154 | 2 | 1.21 (0.99–1.49) | 0.05 | 1.55 (1.06–2.38) | 0.02 |
| Peak RALE score | 154 | 2 | 1.26 (1.05–1.53) | 0.01 | 0.67 (0.41–1.04) | 0.08 |
| Length of hospital stay, days | 153 | 3 | 1.04 (1.01–1.06) | 0.001 | NA | NA |
| Lymphocytes a, × 10⁹/L | 140 | 16 | 0.41 (0.19–0.77) | 0.01 | 0.28 (0.07–0.91) | 0.053 |
| LDH, U/L | 132 | 24 | 1.00 (0.99–1.00) | 0.66 | 0.99 (0.98–0.99) | 0.046 |
| C-reactive protein, mg/L | 139 | 17 | 1.00 (1.00–1.01) | 0.001 | 1.00 (0.99–1.00) | 0.18 |
| Ferritin, ng/mL | 114 | 42 | 1.00 (1.00–1.01) | 0.03 | NA | NA |
| Fibrinogen, g/L | 104 | 52 | 0.99 (0.99–1.00) | 0.47 | 0.99 (0.99–1.00) | 0.18 |
| D-dimer, ng/mL | 138 | 18 | 1.00 (1.00–1.01) | 0.005 | 1.00 (1.00–1.01) | 0.09 |
| Severity group 3 | 156 | 0 | 5.74 (2.58–13.19) | 0.001 | 3.38 (0.66–19.81) | 0.15 |

Variables selected according to backward-forward stepwise selection AIC.

OR odds ratio, CI confidence interval, BMI body mass index, RALE radiographic assessment of lung edema, LDH lactated dehydrogenase

a All laboratory findings are peak values except for lymphocytes which is the lowest value.
four had required invasive mechanical ventilation [13]. Biomedical research proposes models in which the injury underlying viral infection in the lung induces fibrosis by various mechanisms. As mentioned, the elevated fibrosis-related biomarkers seen in these patients indicate that bilateral COVID-19 pneumonia may trigger certain biological pathways [36]. The SARS-CoV-2 infection damages the alveolar epithelium and induces cytokine production; this attracts macrophages that contribute to basement membrane damage and fibroblast activation. Furthermore, hemorrhage due to endothelial injury activates a coagulation cascade that culminates in fibrin deposition. All this contributes to fibrosis of the alveolar space [42].

Whether these changes involve scarring from the acute process or whether they might progress over time is still unclear [43]. Although the virus is eradicated in COVID-19 recovered patients, removing the cause of lung damage does not in itself preclude development of irreversible progressive and fibrotic interstitial lung disease [44]. This study has several limitations. Firstly, data on functional tests or CT scans prior to admission were not available for assessment of longitudinal changes. Secondly, following the study protocol, chest CT was performed initially only in patients with radiological or functional changes at 2 months, and at 12 months when initial CT was altered. This approach aimed to minimize radiological exposure and overload in radiology services during the pandemic, and follows guidelines recommended by several societies [28, 45]. In a small percentage of patients without previous resolution, chest CT at 1 year was not available, so the percentage of fibrotic sequelae could potentially be underestimated. Nonetheless, excluding patients with previous pulmonary interstitial disease or chronic obstructive pulmonary disease, and the fact that these are asymptomatic patients with no functional or chest X-ray alterations after discharge, seem unlikely to result in significant radiological alterations. Likewise, altered DLCO has been described in 98% of patients with fibrosis at the time of initial evaluation, so the percentage of losses in cases of normal DLCO would potentially be low [46]. Another important limitation has been the loss of patients due to pandemic-related restrictions and security measures in pulmonary function laboratories. However, no differences were found between patients who underwent all tests compared to those who did not (Additional file 2: Table S2).

Conclusions
Approximately one third of patients who survived a severe COVID-19 pneumonia had impaired lung function and dyspnea 12 months after hospital discharge, and 23% developed fibrotic-like sequelae, in both severe and mild patients. These findings confirm the need for follow-up of patients with severe SARS-CoV-2-induced pneumonia to clarify whether fibrotic changes may progress over time.

Abbreviations
COVID-19: Coronavirus disease 2019; ARDS: Acute respiratory distress syndrome; SARS: Severe acute respiratory syndrome; MERS: Middle east respiratory syndrome; HRCT: High resolution computed tomography; non-IMV: Non invasive mechanical ventilation; DLCO: Diffusing capacity for carbon monoxide; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; PCR: Polymerase chain reaction; CDC: Centers of disease control; WHO: World Health Organization; SpO2: Oxygen saturation; PaO2/FiO2: Rterial partial pressure of oxygen to fraction of inspired oxygen; ILD: Intersitial lung disease; COPD: Chronic obstructive pulmonary disease; angioCT: Vascular computed tomography; PFT: Pulmonary function test; 6MWT: 6 min-walk test; TLC: Total lung capacity; RV: Residual volumen; FRC: Functional residual capacity; FVC: Forced vital capacity; FEV1: Forced expiratory volume in 1 s; ATS: American Thoracic Society; ERS: European Respiratory Society; CXRs: Chest X-rays; RALE: Radiographic assessment of lung edema; CT: Computed tomography; GGO: Ground-glass opacity; mHRCT: Modified British Medical Research Council; V1: Visit 1; V2: Visit 2; V3: Visit 3; HFNC: High flow nasal cannula oxygen; IMV: Invasive mechanical ventilation; STROBE: Strengthening the Reporting of Observational Studies in Epidemiology; BMI: Body mass index; LDH: Lactated dehydrogenase; MMP: Matrix metalloproteinases.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12931-022-02166-8.

Additional file 1: Figure S1. Interaction plot severity and time in 6MWT based on linear mixed model post-hoc analysis. V1 (2 months), V2 (6 months) and V3 (12 months). Group 1: mild; group 2: moderate; group 3: severe. No between-group differences were found at any time. 6MWT = 6 min walk test.

Additional file 2: Table S1. Chest CT at 2-month follow-up according to severity group. Table S2. Table for reviewer. Characteristics of enrolled patients vs. lost patients.

Acknowledgements
Results partially presented at the 2022 ATS International Conference (7230—Lung Function and CT Lung Abnormalities at 12 Months After Hospital Discharge for COVID-19).

COVID-FIBROTIC study team: Yolanda García (Pulmonary Department, Hospital Clinico, INCLIVA, Valencia, Spain), Natividad Blasco (Pulmonary Department, Hospital Clinico, INCLIVA, Valencia, Spain), Antonio Herrera (Pulmonary Department, Hospital Clinico, INCLIVA, Valencia, Spain), Alba Mulet (Pulmonary Department, Hospital Clinico, INCLIVA, Valencia, Spain), Andrea Ballester (Pulmonary Department, Hospital Clinico, INCLIVA, Valencia, Spain), Antonio Quezada (Pulmonary Department, Hospital Clinico, INCLIVA, Valencia, Spain), Lucia Fernandez (Pulmonary Department, Hospital Clinico, INCLIVA, Valencia, Spain), Noelia Carrion (Pulmonary Department, Hospital General, Valencia, Spain), virginia Molina (Pulmonary Department, Hospital Vinalopó de Elche, Alicante, Spain), Victoria Valentin (Pulmonary Department, Hospital Dr Peset, Valencia, Spain), Irene López (Pulmonary Department, Hospital Dr Peset, Valencia, Spain), Elena Solana-Martinez (Pulmonary Department,
Hospital Virgen de la Arrixaca, Murcia, Spain), Mario Aparicio-Vicente (Pulmonary Department, Hospital Virgen de la Arrixaca, Murcia, Spain), Celia López (Pulmonary Department, Hospital Virgen del Rocío, Sevilla, Spain), Selene Cuenca (Pulmonary Department, Hospital General, Castellon, Spain), Gianna Vargas (Pulmonary Department, Hospital Clínico San Carlos, Universidad Complutense, Madrid, Spain)

Author contributions
JT, BS and JS contributed to the literature search, study design, data interpretation, drafting manuscript and critical revision of the work. JT prepared tables and figures. JAC was the independent statistician and analyzed all data. BS, JT, COV, EFF, JNSC, EN, RA, SH, JAR, JSC, JARP, ALA, MM and JLH collected data and completed data entry. JBS critically revised the manuscript. All authors had full access to all the data and contributed to article writing and editing and approved its submission. JS was responsible for the decision to submit the article. COVID-FIBROTIC study team members supported the implementation, sampling and data submission. All authors read and approved the final manuscript.

Funding
This work was supported by the Institute of Health Carlos III (COVID/20/01209), Ministry of Science and Innovation of Spain.

Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The study (version 3.0, May 2020) was approved by the Research Ethics Committee of Hospital Clínico, INCLIVA (Valencia, Spain) (2020/149) and by local committees where needed. All patients included in the present study agreed voluntarily and gave their written consent. Consent of publication
All patients signed written informed consent prior to pulmonary function testing.

Competing interests
The authors declare that they have no competing interests.

Author details
1Pulmonary Department, Hospital Clínico, INCLIVA, Valencia, Spain. 2Bioinformatics and Biostatistics Unit, INCLIVA, Valencia, Spain. 3Pulmonary Department, Hospital General, Valencia, Spain. 4Pulmonary Department, Hospital San Juan, Alicante, Spain. 5Pulmonary Department, Hospital La Ribera, Alzira, Valencia, Spain. 6Pulmonary Department, Hospital Vinalopo de Elche, Alicante, Spain. 7Pulmonary Department, Hospital Dr Peset, Valencia, Spain. 8Pulmonary Department, Hospital Virgen de la Arrixaca, Murcia, Spain. 9Pulmonary Department, Hospital Arnau de Vilanova, Valencia, Spain. 10Pulmonary Department, Hospital Virgen del Rocío, Sevilla, Spain. 11Pulmonary Department, Hospital los Arcos, Murcia, Spain. 12Pulmonary Department, Hospital General, Castellon, Spain. 13Pulmonary Department, Hospital Clínico San Carlos, Universidad Complutense, Madrid, Spain. 14Pulmonary Department, Hospital La Princesa, Universidad Autónoma, Madrid, Spain.

Received: 5 May 2022 Accepted: 29 August 2022
Published online: 12 September 2022

References
1. WHO. WHO coronavirus (COVID19) dashboard. 2022. www.covid19.who.int. Accessed 4 Mar 2022.
2. Tsatsos SJ, Fischer B, Fischer H, Zeitlinger M. Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. Crit Care. 2020. https://doi.org/10.1186/s13054-020-03240-7.
3. Burnham EL, Janssen WJ, Riches DWH, Moss M, Downey GP. The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance. Eur Respir J. 2014. https://doi.org/10.1183/09031936.00196412.
4. Burnham EL, Hyzy RC, Paine R, et al. Chest CT features are associated with poorer quality of life in acute lung injury survivors. Crit Care Med. 2013. https://doi.org/10.1097/CCM.0b013e31826a5062.
5. Masclans JR, Roca O, Muriz X, et al. Quality of life, pulmonary function, and tomographic scan abnormalities after ARDS. Chest. 2011. https://doi.org/10.1378/chest.10-2438.
6. Ahmed H, Patel K, Greenwood DC, et al. Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalization or ICU admission: a systematic review and meta-analysis. J Rehabil Med. 2020. https://doi.org/10.2340/16501977-2694.
7. Hui DS, Joyn MT, Wong KT, et al. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax. 2005;60:401–9.
8. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016. https://doi.org/10.1136/rivh.2004.030205.
9. Tse GM, To KF, Chan PK, et al. Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J Clin Pathol. 2004. https://doi.org/10.1136/jcp.2003.013276.
10. Kommoss FF, Schwab C, Tavener L, et al. The pathology of severe COVID-19-related lung damage. Dtsch Arztebl Int. 2020. https://doi.org/10.3238/arztebl.2020.0500.
11. Combet M, Pavot A, Salave L, Humbert M, Monnet X. Rapid onset honeycomb fibrosis in spontaneously breathing patient with COVID-19. Eur Respir J. 2020. https://doi.org/10.1183/13993003.01808-2020.
12. Sommerweber T, Sahanic S, Pizzini A, et al. Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial. Eur Respir J. 2021. https://doi.org/10.1183/13993003.03481-2020.
13. Han X, Fan Y, Alvalid O, et al. Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Radiology. 2021. https://doi.org/10.1148/radiol.2021203153.
14. Fan P, Yang L, Liang B, et al. Chest CT patterns from diagnosis to 1 year of follow-up in COVID-19. Radiology. 2021. https://doi.org/10.1148/radiol.2021211199.
15. Wu X, Liu X, Zhou Y, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021. https://doi.org/10.1016/S2213-2600(21)00174-0.
16. National Institutes of Health. NIH covid-19 treatment guidelines. Clinical spectrum of SARS-CoV-2 infection. 2021. www.covid19treatmentguidelines.nih.gov/. Accessed 14 Nov 2021.
17. Wong HYF, Lam H, Fong AH-T, et al. Frequency and distribution of chest radiographic findings in COVID-19 positive patients. Radiology. 2020. https://doi.org/10.1148/radiol.2020201160.
18. Graham BL, Brusasco V, Burgos F, et al. ERS/ATS standards for single-breath carbon monoxide uptake in the lung. Eur Respir J. 2017. https://doi.org/10.1183/13993003.00016-2016.
19. Graham BL, Steenbruggen I, Miller MR, et al. Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med. 2019. https://doi.org/10.1164/rccm.201910-1590ST.
20. Quanjer PH, Stanojevic S, Cole T, et al. Multi-ethnic reference values for spirometry for the 3–95-year age range: the global lung function 2012 equations. Eur J Resp. 2012. https://doi.org/10.1183/09031936.00031912.
21. Stanojevic S, Graham BL, Cooper BG, et al. Official ERS technical standards: global lung function initiative reference values for the carbon monoxide transfer factor for Caucasians. Eur Resp J. 2017. https://doi.org/10.1183/13993003.00010-2017.
22. Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Resp J. 2014. https://doi.org/10.1183/09031936.00150314.
23. ATS Committee on Prophylaxis Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002. https://doi.org/10.1164/rccm.166.2.711.
24. Hansell DM, Bankier AA, MacMahon H, Mcloud TC, Muller NL, Remy J. Fleischner society: glossary of terms for thoracic imaging. Radiology. 2008. https://doi.org/10.1148/radiol.2462070712.
25. Antonio GE, Wong KT, Hui DSC, et al. Thin-section CT in patients with severe acute respiratory syndrome following hospital discharge: preliminary experience. Radiology. 2003. https://doi.org/10.1148/radiol.2283030726.

26. Westcott JL, Cole SR. Traction bronchiectasis in end-stage pulmonary fibrosis. Radiology. 1986. https://doi.org/10.1148/radiology.161.3.3786716.

27. Bestall JC, Paul EA, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999. https://doi.org/10.1136/thx.54.7.581.

28. Sibilia O, Molina-Molina M, Valenzuela C, et al. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) consensus for post-COVID-19 clinical follow-up. Open Respir Arch. 2020. https://doi.org/10.1016/j.opresp.2020.09.002.

29. WHO. Treatment trial design master protocol synopsis final 18022020. www.who.int/blueprint/priority-diseases/key-action/COVID-19. 2020. Accessed 9 Nov 2021.

30. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The strengthening of reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007. https://doi.org/10.1016/S0140-6736(07)61602-X.

31. Hui DS, Wong KT, Ko FW, et al. The 1-year impact of severe acute respiratory syndrome following hospital discharge: preliminary maps and institutional affiliations. Open Respir Arch. 2020. https://doi.org/10.1016/j.opresp.2020.09.002.

32. Cabrera-Benitez NE, Laffey JG, Parotto M, et al. Mechanical ventilation-associated lung fibrosis in acute respiratory distress syndrome: a significant contributor to poor outcome. Anesthesiology. 2014. https://doi.org/10.1097/ALN.000000000000264.

33. Dennis JM, McGovern AP, Vollmer SJ, Mateen BA. Improving survival of critically ill patients with coronavirus disease 2019 in England—a national cohort study, March to June 2020. Crit Care Med. 2021. https://doi.org/10.1097/CCM.0000000000004747.

34. Fabbri L, Moss S, Khan FA, et al. Parenchymal lung abnormalities follow- ing hospitalization for COVID-19 and viral pneumonitis: a systematic review and meta-analysis. Thorax. 2022. https://doi.org/10.1136/thoraxjnl-2021-218275.

35. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2020. https://doi.org/10.1016/S0140-6736(20)32658-6.

36. Saifoti B, Tarraso J, Rodriguez-Bonja E, et al. Lung function, radiological findings and biomarkers of fibrogenesis in a cohort of COVID-19 patients six months after hospital discharge. Arch Bronconeumol. 2022. https://doi.org/10.1016/j.arbes.2021.08.014.

37. Satturwar S, Fowkes M, Farver C, et al. Postmortem findings associated with SARS-CoV-2 systematic review and meta-analysis. Am J Surg Pathol. 2021. https://doi.org/10.1097/PAS.0000000000001650.

38. Li Y, Wu J, Wang S, et al. Progression to fibrosing diffuse alveolar damage in a series of 30 minimize invasive autopsies with COVID-19 pneumonia in Wuhan, China. Histopathology. 2021. https://doi.org/10.1111/his.14249.

39. Martinez-Jiménez S, Rosado-de-Christenson ML, Carter BW. Speciality imaging: HRCT of the lung e-book. Amsterdam: Elsevier Health Sciences; 2017. https://doi.org/10.1016/B978-0-323-52477-3.50078-0.

40. Watanabe A, So M, Iwagami M, et al. Persistent post-COVID-19 interstitial lung disease: An observational study of corticosteroid treatment. Ann Am Thorac Soc. 2021. https://doi.org/10.1513/AnnalsATS.202008-1022OC.

41. Jonh AE, Joseph C, Jenkins G, Tatler AL. COVID-19 and pulmonary fibrosis: a potential role for lung epithelial cells and fibroblasts. Immunol Rev. 2021. https://doi.org/10.1111/imr.12977.

42. Solomon J, Heyman B, Ko JP, Condos R, Lynch DA. Post-acute lung complications of COVID-19. Radiology. 2021. https://doi.org/10.1148/radiol.202121536.

43. Spagnolo P, Balestrio E, Aiberti S, et al. Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Respir Med. 2020. https://doi.org/10.1016/S2213-2600(20)30222-8.

44. George PM, Barratt SL, Condliffe R, et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020. https://doi.org/10.1136/thoraxjnl-2020-215314.

45. Planter L, Cazes A, Dinh-Xuan AT, Bancal C, Marchand-Adam S, Crestani B. Physiology of the lung in idiopathic pulmonary fibrosis. Eur Respir Rev. 2018. https://doi.org/10.1183/16000617.0062-2017.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.